Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innocan Pharma Corp C.INNO

Alternate Symbol(s):  INNPF

Healthcare
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of... see more

Recent & Breaking News (CSE:INNO)

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Canada NewsWire 3 days ago

Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M

Canada NewsWire April 1, 2024

Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.

Canada NewsWire March 25, 2024

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million

Canada NewsWire March 14, 2024

Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study

Canada NewsWire March 5, 2024

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Canada NewsWire February 26, 2024

Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024

Canada NewsWire February 20, 2024

Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST

Canada NewsWire February 5, 2024

Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration

Canada NewsWire December 12, 2023

Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from a prolong use in animals

Canada NewsWire November 3, 2023

Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research

Canada NewsWire October 23, 2023

Innocan Pharma Announces Closing of Second and Final Tranche of Financing

Canada NewsWire October 20, 2023

Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update

Canada NewsWire October 12, 2023

Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million

GlobeNewswire September 21, 2023

Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board

Canada NewsWire September 15, 2023

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

Canada NewsWire September 5, 2023

Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

Canada NewsWire August 29, 2023

Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022

Canada NewsWire August 25, 2023

Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment

Canada NewsWire August 15, 2023

Innocan Pharma Announces Closing of Private Placement

Canada NewsWire August 4, 2023